Ajanta Pharma has earmarked a capex plan of Rs 250 crore for FY22. The company is likely to use the same towards maintenance and some new expansions for the corporate office and some key expansions in the facility. The company operates eight manufacturing facilities in India and Mauritius, including two plants which have been approved by the US Food and Drug Administration (USFDA).
Earlier, the company had earmarked a capex plan of Rs 150 crore for the 2019-20 fiscal. The company had invested Rs 30 crore in the expansion of the corporate office last year, and this year it is going to be in the range of Rs 60-80 crore.
Ajanta Pharma is a specialty pharmaceutical company engaged in development, manufacturing and marketing of quality finished dosages.
